Clinical Trials Logo

Filter by:
NCT ID: NCT06266858 Recruiting - Clinical trials for Mitral Regurgitation

Multimodality Imaging Assessment of the Severity of Mitral Regurgitation

Start date: December 1, 2022
Phase: N/A
Study type: Interventional

To investigate to assess the severity of mitral regurgitation by multimodality imaging.

NCT ID: NCT06266832 Recruiting - Clinical trials for Rectal Adenocarcinoma

The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal Adenocarcinoma

Start date: January 1, 2024
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy, safety and organ retention rate of short-course radiation combined with Adebrelimab and CAPEOX neoadjuvant therapy in patients with MSS/pMMR ultra low rectal adenocarcinoma.

NCT ID: NCT06266715 Recruiting - Depression Clinical Trials

Improvement of Depression With Use of ATP

Start date: March 4, 2024
Phase: N/A
Study type: Interventional

This clinical study is a randomized, double-blind, placebo-controlled trial with an intervention period of 4 weeks. Participants will be patients with moderate to severe depression who meet the inclusion criteria during the screening period. After recruitment written informed consent form will be signed and the baseline evaluation will be done then the treatment period follows. The subjects will be randomly assigned to a control group (escitalopram plus normal saline(NA)) and an ATP group (escitalopram plus adenosine disodium triphosphate(ATP)) in a 1:1 ratio for treatment, with a total number of 120 recruited patients. Assessment will be carried out as an analysis of changes in Hamilton Depression Scale(HAMD-24), cognitive function test, brain functional network, inflammatory markers, and other indicators in the first, second, and fourth week of intervention which will evaluate the effectiveness of ATP in improving moderate to severe depression preliminarily.

NCT ID: NCT06266520 Recruiting - Acute Ankle Sprain Clinical Trials

MNK Therapy in Releasing the Superficial Fascia for Patients With AAS: an Assessor-blinded, Randomised Controlled Trial

Start date: January 1, 2023
Phase: N/A
Study type: Interventional

The goal of this type of randomized controlled trial, employing a blinded evaluator methodology, to verify the clinical efficacy and safety of MNK therapy. This aims to provide a reference for clinical practitioners and AAS patients in their decision-making process. Participants will randomly allocated into two groups using a random number table method, with forty patients in each group. The experimental group (Group 1) underwent MNK therapy to release the superficial fascia, while the control group (Group 2) received conventional acupuncture treatment.

NCT ID: NCT06265428 Recruiting - Clinical trials for HER2-positive Breast Cancer

A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer

Start date: January 29, 2024
Phase: Phase 3
Study type: Interventional

This study is designed to compare efficacy and safety of DB-1303/BNT323 versus T-DM1 in HER2-positive, unresectable and/or metastatic breast cancer patients previously treated with trastuzumab and taxane.

NCT ID: NCT06265350 Recruiting - Clinical trials for Hepatocellular Carcinoma

Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases

Start date: February 2, 2024
Phase: N/A
Study type: Interventional

This study intends to evaluate the efficacy and safety of cryoablation combined with Cardonilizumab and Bevacizumab in hepatocellular carcinoma with pulmonary metastases.

NCT ID: NCT06265311 Recruiting - Ultrasonography Clinical Trials

IDUS in CBD Stone Recurrence High Risk Patients

Start date: November 2, 2021
Phase: N/A
Study type: Interventional

This study is designed to observed CBD stones cases with high recurrence risks applying IDUS or not during ERCP. Patients with CBD stone high recurrence risks were enrolled in this study, and prospectively randomized into IUDS group and control group during lithotomy. Operation time, radiation time, hospitalization cost, retain of nasobiliary tube, deployment of stent were recorded. Symptoms and conditions after ERCP were also followed up including blood amylase, routine blood test, abdominal pain, post-ERCP pancreatitis, resection of gallbladder, recurrence of CBD stone and onset of cholangitis.

NCT ID: NCT06265155 Recruiting - Clinical trials for Triggers of Acute Ischemic Stroke Due to Large Vessel Occlusion

Triggers of Acute Ischemic Stroke Due to Large Vessel Occlusion

Start date: February 1, 2024
Phase:
Study type: Observational

Acute ischemic stroke has a high incidence, ischemic stroke caused by large vessel occlusion is serious and has a poor prognosis, and its triggers in the short term before onset are not clear. The aim of this study was to evaluate the short-term risk of acute ischemic stroke caused by multiple triggers. In this trial, through a case-crossover study design, patients were asked about the exposure to each trigger in the previous year and the exposure during the preictal risk period (the exposure observed during the risk period) for each potential trigger of acute ischemic stroke caused by large vessel occlusion. To evaluate the relative risk of ischemic stroke resulting from exposure to triggers, comparing exposure during the dangerous period with the usual frequency of exposure. Relative risks and corresponding 95% CIs were estimated for past-year exposure and past-year mean exposure (assessed as chronic risk factors) and time to last exposure (assessed as triggers). Scientifically evaluate exposure to a range of potential triggers, including infection, mood, smoking, alcohol consumption, diarrhea and vomiting, extreme temperature changes, and several factors that increase blood pressure and their risk of developing acute ischemic stroke.

NCT ID: NCT06265051 Recruiting - Clinical trials for Acute Ischemic Stroke

Tirofiban After Successful MT Recanalization in AIS

ATTRACTION
Start date: April 9, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

Acute ischemic stroke with large vessel occlusion is a frequently occurring life-threatening condition. Although endovascular treatment can effectively open occluded vessels, the successful reperfusion rate exceeds 80%, but the rate of good prognosis is less than 50%. The current clinical focus is on how to improve futile recanalization. Tirofiban is widely used in the treatment of stroke, as it can effectively prevent vascular reocclusion and improve microcirculation perfusion. It has the potential to improve futile recanalization, but there is a lack of high-level evidence-based medical support. This multicenter, prospective, double-blind, randomized controlled trial was conducted to assess the effectiveness and safety of sequential tirofiban therapy following successful mechanical thrombectomy within 24 hours of onset.

NCT ID: NCT06264804 Recruiting - Refractive Surgery Clinical Trials

Risk Factors for Progressive Suction Loss in Corneal Refractive Surgery

Start date: February 16, 2024
Phase:
Study type: Observational

The goal of this Prospective observational studiesis to Characteristics of progressive suction loss.